Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Virchows Archiv : an International Journal of Pathology|November 25, 2018
Adoptive cellular therapies: the current landscapeMaartje W Rohaan, Sofie Wilgenhof, John B A G Haanen
Journal for Immunotherapy of Cancer|October 5, 2018
Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment optionMaartje W Rohaan, Joost H van den Berg, Pia Kvistborg, et al.
Neonatology|February 18, 2016
Severe Neonatal Anaemia, MRI Findings and Neurodevelopmental OutcomeInge A Zonnenberg, R Jeroen Vermeulen, Maartje W Rohaan, et al.
BMC Cancer|August 4, 2022
Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trialMaartje W Rohaan, Emma H A Stahlie, Viola Franke, et al.
Oncology Research and Treatment|April 7, 2024
Intradermal Naked DNA Vaccination by DNA Tattooing for Mounting Tumor-Specific Immunity in Stage IV Melanoma Patients: A Phase I Clinical TrialMarnix H Geukes Foppen, Maartje W Rohaan, Jessica S W Borgers, et al.
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|July 12, 2019
Sensorineural Hearing Loss After Adoptive Cell Immunotherapy for Melanoma Using MART-1 Specific T Cells: A Case Report and Its PathophysiologyCharlotte W Duinkerken, Maartje W Rohaan, Vincent A de Weger, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 21, 2021
Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell responseAnastasia Gangaev, Elisa A Rozeman, Maartje W Rohaan, et al.
Journal for Immunotherapy of Cancer|January 21, 2025
Art of TIL immunotherapy: SITC's perspective on demystifying a complex treatmentSimon Turcotte, Marco Donia, Brian Gastman, et al.
Journal for Immunotherapy of Cancer|March 26, 2024
Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trialRenske M T Ten Ham, Maartje W Rohaan, Inge Jedema, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2026
Phenotypic and Functional Characteristics of CD8+ T cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced MelanomaJoachim S Granhøj, Sigrid M H Mannering, Kasper Madsen, et al.
Pageof 2